Canadian Meds |
Policy | Legal
Terms | Meds Index
Vastarel, a trimetazidine-based medication, belongs to the group of drugs that enhance the metabolism in the tissues and organs of the neurosensory myocardial abnormalities in their conditions of circulation (ischemia). Pharmacological action of Vastarel consists in normalizing the process of education and consumption of energy (energy metabolism) cells experiencing oxygen deficiency due to impaired blood circulation.
Vastarel prevents a decrease in the intracellular concentration of adenosine triphosphate (ATP), which is the main source of energy needed to maintain normal cell activity. Additionally, the drug promotes normal functioning of ionic membrane channels, thus maintaining a constant internal environment (homeostasis) of cells. The instructions to trimetazidine notes that the administration increases resistance to lack of oxygen in myocardial cell, the hearing aid and the retina. In patients with angina it can reduce the frequency of attacks and increase the stability of the myocardium (tolerance) to physical stress.
Also, during Vastarel therapy the use of nitroglycerin is substantially reduced. According to trimetazidine researches, the medication improves hearing and reduces, and in some cases completely eliminates the dizziness issues in Meniere's disease. When ingested, Vasteral almost completely and very rapidly absorbed through the mucous membranes of the gastrointestinal tract. Its bioavailability equals 90%. The maximum concentration is built in the blood two hours after taking the initial dose. The drug is excreted mainly by kidneys in unchanged form. Indications Trimetazidin The drug is used for long-term treatment of coronary heart disease, as part of combined therapy, and as monotherapy.
Vastarel pharmacokinetics: excretion and absorption
The drug is rapidly absorbed rapidly: Cmax (maximum concentration in blood) is achieved after 5 hours since the administration. The concentration in plasma remains at a level exceeding 75%; food intakes do not affect the pharmacokinetic properties of the drug. The preparation is mainly excreted by the kidneys in unchanged form.
The preparation is largely utilized in cardiology: prolonged therapy of coronary artery disease, stable angina attacks prevention (applied as monotherapy or combination therapy), ENT diseases, including treatment of vestibular disorders cochle-ischemic nature, such as dizziness, tinnitus, hearing impairment. The medication is also used in ophthalmology to treat chorioretinal disorders with ischemic component.
The dosage depends on the particular case; however, the preparation is typically appointed at a dose of 1 tablet 2 times a day during meals in the morning and evening. The tablets are taken orally as a whole, without chewing and drinking water. The duration of therapy is determined individually. Consult your treating doctor to determine the optimal dose.
Even though the preparation is referred to well-tolerated class, administering the drug should be avoided in case of severe renal impairment (creatinine clearance rate is less than 15 mL/min) and hypersensitivity to the drug.
Due to lack of sufficient clinical data it is not recommended to prescribe a drug for children and adolescents under the age of 18 years. Precautions should be prescribed to patients with severe hepatic insufficiency (clinical researches data is limited).
© 2003-2017 Rx Meds Canada . All Rights Reserved